ASCO 2023 | Safety analysis of TROPHY-U-01 based on UGT1A1 status in mUC

Yohann Loriot, MD, PhD, Gustave Roussy, Villejuif, France, discusses the cohort 1 findings from the Phase II TROPY-U-01 study (NCT03547973), which evaluated the safety and efficacy of the antibody-drug conjugate sacituzumab govetican (SG) in patients with metastatic urothelial carcinoma (mUC), who had previously received platinum-based chemotherapy and immune checkpoint inhibitors. In this report, the authors provide updated safety outcomes based on the UGT1A1 status of the patients. The incidence of treatment-related adverse events varied across UGT1A1 subgroups, with homozygous patients experiencing higher rates of adverse events, dose interruptions, and dose reductions. Additional studies such as the TROPiCS-04 trial (NCT04527991) are needed to confirm the impact of UGT1A1 status on safety outcomes with SG in urothelial carcinoma. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.